抗CD44抗体治疗急性髓系白血病的研究进展

Advances in the Research of Anti-CD44 Monoclonal Antibodies Mediated Therapy in Acute Myeloid Leukemia

CD44分子是一种广泛分布的细胞表面跨膜糖蛋白,在许多方面发挥着重要的生理和病理作用,其中之一就是CD44分子参与血细胞的生成,在血细胞分化成熟的过程中发挥着关键性作用。CD44与一些特异的抗体结合后能够逆转急性髓系白血病幼稚细胞的分化阻滞,从而逆转其恶性细胞的表型,最终使肿瘤细胞的抗原性、功能和细胞生物学特征与正常分化的骨髓系细胞相一致。

CD44 is a widely distributed cell-surface glycoprotein involved in a variety of physiological and pathological processes. It plays a key role in the regulation of normal hematopoiesis, and especially it can induce terminal differentiation of hematopoietic stem/progenitor cells. CD44-ligation with specific monoclonal antibodies （H90, A3D8 and HI44a） can reverse the differentiation blockage of leukemic blasts in some AML subtypes （ from M1 to M5 ）, and subsequently it can transform the cytologic and antigenic features of AML malignant cells to those of normal myeloid cells, This paper reviews the differentiative and apoptotic effects of anti-CD44 mAbs in AML cells and their possible mechanisms and the prospect of using CD44-targated therapy for AML.